oral vaccine nmdar1 efficacy experimental stroke epilepsy 
brain generally considered immunoprivileged although increasing examples immunological responses brain antigens neuronal expression major histocompatibility class genes neurological autoimmunity recognized adeno-associated virus aav vaccine generated autoantibodies targeted specific brain protein nr1 subunit n-methyl-d-aspartate nmda receptor peroral administration aav vaccine transgene expression persisted least months associated robust humoral response absence significant cell-mediated response single-dose vaccine associated strong anti-epileptic neuroprotective activity rats kainate-induced seizure model also middle cerebral artery occlusion stroke model months following vaccination thus vaccination strategy targeting brain proteins feasible may therapeutic potential neurological disorders 
